SCHEMBL70192

SCHEMBL70192

CCOC(=O)CNC(=O)c1ccc(Nc2ccccc2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
HCAR3 P49019 1/20 0.56
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 1/20 0.48
PPID Q08752 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
GRM5 P41594 1/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
TP53 P04637 1/20 0.46
GLA P06280 1/20 0.46
DGAT1 O75907 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70737 0.83 RAB9A (0.60) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL71247 0.83 HCAR3 (0.66) MAPTHCAR3NPC1RAB9AKDM4E
SCHEMBL70586 0.82 HCAR3 (0.64) MAPTHCAR3NPC1RAB9ASMN1; SMN2
SCHEMBL27851429 0.79 MAPT (0.60) MAPTHCAR3NPC1RAB9ASMN1; SMN2
SCHEMBL1221369 0.77 RAB9A (0.66) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL71677 0.77 HPGD (0.48) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL71818 0.75 RAB9A (0.66) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1332232 0.75 MAPT (0.84) MAPTHCAR3NPC1RAB9ASMN1; SMN2
SCHEMBL9076442 0.75 HCAR3 (0.73) MAPTHCAR3NPC1RAB9AKDM4E
SCHEMBL64414 0.74 HCAR3 (0.71) MAPTHCAR3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 MAPT 3456/4885HCAR3 443/4885NPC1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.